• Schrödinger co-founded Tectora with NEA, RA Capital, signing a licensing and collaboration deal to advance immunology, inflammation drug programs.
• Tectora closed a USD 55 million Series A led by NEA, RA Capital to fund development.
• Schrödinger contributed two early-stage small-molecule assets, receiving equity plus potential milestones, royalties.
• Tectora will use Schrödinger’s computational platform, drug discovery team to move the programs toward clinical candidates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schrodinger Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609090700BIZWIRE_USPR_____20260909_BW340138) on September 09, 2026, and is solely responsible for the information contained therein.